[Skip to Content]
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
January 2013

Thiopurines and Risk of Nonmelanoma Skin Cancer in Inflammatory Bowel Disease

Author Affiliations
 

SECTION EDITOR: MICHAEL BIGBY, MD; ASSISTANT SECTION EDITORS: OLIVIER CHOSIDOW, MD, PhD; ROBERT P. DELLAVALLE, MD, PhD, MSPH; DAIHUNG DO, MD; URBÀ GONZÁLEZ, MD, PhD; CATALIN M. POPESCU, MD, PhD; HYWEL WILLIAMS, MSc, PhD, FRCP

JAMA Dermatol. 2013;149(1):92-94. doi:10.1001/2013.jamadermatol.616

Commentary on: Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel diseaseSingh H, Nugent Z, Demers AA, Bernstein CN Gastroenterology. 2011;141(5):1612-1620

Questions: Is there an increased risk of nonmelanoma skin cancer (NMSC) for patients with inflammatory bowel disease (IBD)? Is there an increased risk of NMSC if they receive immunosuppressive therapy?

Design: Historical cohort study and nested case-control study.

First Page Preview View Large
First page PDF preview
First page PDF preview
×